Current Clinical Trials

How to Participate/Find a Trial

If you want to discuss clinical research trials, and you are already a patient, ask your provider at your next visit. Alternatively, or If you are not a current patient, you can call the HOA Research Department at 315-472-7504, extension 1350.

A list of HOA’s current clinical trials that are recruiting new patients is below. The list is grouped by disease.

If you are looking for a trial that is not listed here, please contact us as we may be able to open a trial for eligible patients. 

For a complete list of all available clinical trials nationwide, visit, a website maintained by the National Insitutes of Health -- which is the research arm of the Department of Health and Human Services.


Breast Pfizer-C4891001

VERITAC-2- Open-Label Trial of ARV-471 (PF-07850327) vs. Fulvestrant in PTS W/ ER-Positive, HER2-Negative Advanced Breast Cancer w/ Disease Progression After Prior Endocrine Rx For Advanced Disease

Breast, A011801

CompassHer2 Residual Disease (RD): Double-Blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared with T-DM1 and Tucatinib

Breast, A191901

Optimizing Endocrine Therapy Through Motivational Interviewing and Text Interventions- "Get Set"

Breast, Ascent 03

Trodelvy vs MD Choice for Untreated PD-L1 Negative mTNBC or PD-L1 Positive Previously Treated w/ Anti PD-L1 Therapy Who Recur

Breast, CELC-G-301

Viktoria-1 Gedatolisib in Combination with Palbociclib and Fulvestrant Compared to SOC in Previously Treated Pts with HR-Positive, HER2 Negative Advanced Breast Cancer

Breast, EA1181

CompassHer2-pCR-Preoperative THP and Postoperative HP in Patients who Achieve a Pathologic Complete Response

Breast, NRG-BR007

DEBRA-De-escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18

Breast, TOL2506A

Ovarian Suppression Evaluating Subcutaneous LeuprolIde Acetate in Breast Cancer (OVELIA)

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), S1925

Early Intervention with Venetoclax and Obinutuzumab Versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with CLL/SLL


Colorectal, A021703

Vitamin D3 with Chemotherapy and Bevacizumab in Treating Patients With Advanced or Metastatic Colorectal Cancer (SOLARIS)

Colorectal, A221805

Duloxetine to Prevent Oxaliplatin-Induced Chemotherapy-Induced Peripheral Neuropathy

Colorectal, NRG-GI005

Circulating Tumor DNA as a Predictive Biomarker in Adjuvant Chemotherapy in Patients with Stage IIA Colon Cancer (COBRA)


Esophageal, MK-7902-014

Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014)


Immunotherapy, A151804

Collection of Research Data and Samples From Patients Who Experience Immunotherapy Side Effects


Kidney, A031704

Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study


Lung, 61186372NSC2002

A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer (PALOMA-2)

Lung, 849-017

Adagrasib in Patients with Advanced NSCLC with KRAS G12C Mutation (Krystal 17)

Lung, A081801

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, ALCHEMIST Chemo-IO Study

Lung, A151216

Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)

Lung, A171901

Testing the Effects of MK-3475 (Pembrolizumab) With or Without the Usual Chemotherapy Treatment for Patients 70 Years of Age and Older With Advanced Non-small Cell Lung Cancer

Lung, EA5163

Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer

Lung, EA5181

Durvalumab as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC

Lung, Keynote-867

Efficacy and Safety Study of Stereotactic Body Radiotherapy (SBRT) With or Without Pembrolizumab (MK-3475) in Adults With Unresected Stage I or II Non-Small Cell Lung Cancer (NSCLC) (MK-3475-867/KEYNOTE-867)

Lung, NRG-LU007

Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial

Lung, Pacific 4-D9103C00001

Durvalumab vs Placebo With Stereotactic Body Radiation Therapy in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients / Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation (PACIFIC-4)

Lung, S1827

Testing Whether the Use of Brain Scans Alone Instead of Brain Scans Plus Preventive Brain Radiation Affects Lifespan in Patients With Small Cell Lung Cancer (MAVERICK)

Myelodisplastic Syndrome (MDS)

Myelodisplastic Syndrome (MDS)

A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Participants With International Prognostic Scoring System Revised (IPSS-R) Low- or Intermediate-risk Myelodysplastic Syndrome (MDS)

Myeloid Diseases (Primary Myelofibrosis, Myelodysplastic Syndrome, Acute Myeloid Leukemia)

Myeloid Diseases (Primary Myelofibrosis, Myelodysplastic Syndrome, Acute Myeloid Leukemia), AZA-MDS-006

Connect MDS and AML Registry


Neuroendocrine, A021602

Cabozantinib Versus Placebo in Patients with Advanced Neuroendocrine Tumors After Progression On Prior Therapy (CABINET)

Solid Tumor

Solid Tumor, JZP712-201

Lurbinectedin Monotherapy in Participants With Advanced or Metastatic Solid Tumors (Urothelial Cancer or Large Cell Neuroendocrine Cancer of Lung or Homologous Recombination Defiecient-Positive Advanced endometrial, biliary tract, urothelial, breast, pancreatic, gastric or esophageal tumor irrespective of PD-L1 (EMERGE-201)

Solid Tumor, RAIN-3202 (MANTRA-2)

Basket Study of Milademetan in Advanced/Metastatic Solid Tumor for patients whose tumor tissue or blood displays MDM2 amplification and is TP53 normal